Preeclampsia biomarkers and use thereof
AssigneeInnovatio Pty Ltd
InventorLana McClements
Life of this patent
Estimating the term…
Abstract
Biomarkers and combinations thereof for determining risk and onset of preeclampsia, methods for their use and for diagnosis, prediction of risk, management, and treatment of preeclampsia in pregnant human females are provided.
Claims51
A method of determining risk for developing preeclampsia in a pregnant female human subject, the method comprising detecting the level of CD44 in a biological sample of the subject using an agent binding CD44, wherein a level of the CD44 above a predetermined threshold in the sample is indicative of an increased risk for the subject to develop preeclampsia at or after gestational week 30.
A method of determining risk for developing preeclampsia in a pregnant female human subject, the method comprising:
- a) detecting the level of CD44 and the level of FKBPL in a biological sample of the subject using an agent binding CD44 and an agent binding FKBPL,
- b) determining the ratio of CD44/FKBPL in the sample,
- c) wherein a ratio of CD44/FKBPL above a predetermined threshold in the sample is indicative of an increased risk for the subject to develop preeclampsia at or after gestational week 30.
A method for managing pregnancy in a pregnant female human subject at gestational week 20-30, the method comprising:
- a) detecting the level of CD44 in a biological sample of the subject using an agent binding CD44,
- b) wherein a level of the CD44 is above a predetermined threshold in the sample, referring the subject for high risk pregnancy management.
A method for managing pregnancy in a pregnant female human subject at gestational week 15-30, the method comprising:
- a) detecting the level of CD44 and the level of FKBPL in a biological sample of the subject using an agent binding CD44 and an agent binding FKBPL,
- b) determining the ratio of CD44/FKBPL in the sample,
- c) wherein a ratio of CD44/FKBPL is above a predetermined threshold in the sample, referring the subject for high risk pregnancy management.
A method of treating a pregnant female human subject for preeclampsia, the method comprising:
- a) detecting the level of CD44 in a biological sample of the subject using an agent binding CD44, wherein the biological sample is of gestational week 20-30,
- b) wherein a level of the CD44 in the biological sample is above a predetermined threshold, testing the subject for at least one indicator of preeclampsia, and
- c) wherein the at least one indicator of preeclampsia is positive, treating the subject for preeclampsia at or after gestational week 30.
A method of treating a pregnant female human subject for preeclampsia, the method comprising:
- a) detecting the level of CD44 and a level of FKBPL in a biological sample of the subject using an agent binding CD44 and an agent binding FKBPL, wherein the biological sample is of gestational week 15-30,
- b) wherein a ratio of the CD44/FKBPL levels in the biological sample is above a predetermined threshold, testing the subject for at least one indicator of preeclampsia, and
- c) wherein the at least one indicator of preeclampsia is positive, treating the subject for preeclampsia at or after gestational week 30.
A method of treating a pregnant female human subject for preeclampsia, the method comprising:
- a. detecting the level of CD44 and a level of FKBPL in a first biological sample of the subject using an agent binding CD44 and an agent binding FKBPL, wherein the first biological sample is of gestational week 15-30,
- b) detecting the level of CD44 and a level of FKBPL in a second biological sample of the subject using an agent binding CD44 and an agent binding FKBPL, wherein the second biological sample is of gestational week later than gestational week 30,
- c) wherein a ratio of the CD44/FKBPL levels in the first biological sample is above a first predetermined threshold and a ratio of the CD44/FKBPL levels in the second biological sample is below a second predetermined threshold, testing the subject for at least one indicator of preeclampsia, and
- d) wherein the at least one indicator of preeclampsia is positive, treating the subject for preeclampsia.
A method of treating a pregnant female human subject for preeclampsia, the method comprising:
- a) detecting the level of CD44 in a biological sample of the subject using an agent binding CD44, wherein the biological sample is of gestational week later than gestational week 30,
- b) wherein a level of the CD44 in the biological sample is below a predetermined threshold, testing the subject for at least one indicator of preeclampsia, and
- c) wherein the at least one indicator of preeclampsia is positive, treating the subject for preeclampsia.
A method of treating a pregnant female human subject for preeclampsia, the method comprising:
- a) detecting the level of CD44 and a level of FKBPL in a biological sample of the subject using an agent binding CD44 and an agent binding FKBPL, wherein the biological sample is of a gestational week later than gestational week 30,
- b) wherein a ratio of the CD44/FKBPL levels in the biological sample is below a predetermined threshold, testing the subject for at least one indicator of preeclampsia, and
- c) wherein the at least one indicator of preeclampsia is positive, treating the subject for preeclampsia.
A composition-of-matter comprising a biological sample of a pregnant female human subject comprising an agent binding CD44 and an agent binding FKBPL.
A composition of matter comprising:
- a) a first portion of a biological sample of a pregnant female human subject comprising an agent binding CD44, and
- b) a second portion of the biological sample of the pregnant female human subject comprising an agent binding FKBPL.
A diagnostic kit for use in diagnosing preeclampsia or risk to develop preeclampsia in a pregnant female human subject, the kit comprising:
- (a) a first agent which specifically binds soluble CD44, wherein the first agent is detectably labeled or coupled to an enzyme;
- (b) a normal reference sample for CD44, wherein the normal reference sample for CD44 is a sample containing a level of CD44 found in a pregnant human female subject not having preeclampsia or risk to develop preeclampsia;
- a pregnant human female subject not having early-onset preeclampsia or eclampsia;
- (c) a second agent which binds soluble FK 506 Binding Protein Like (FKBPL) wherein the second agent is detectably labeled or coupled to an enzyme and (d) a normal reference sample for FKBPL, wherein the normal reference for FKBPL sample is a sample containing a level of FKBPL found in a pregnant human female subject not having preeclampsia or risk to develop preeclampsia;
- a pregnant human female subject not having early onset preeclampsia.
An agent for treatment of preeclampsia for use in a pregnant human female subject exhibiting a level of CD44:
- a) greater than a predetermined threshold in a biological sample therefrom, wherein the sample is from 20-30 weeks gestation;
- or
- b) lower than a second predetermined threshold, wherein the sample is from 30 or more weeks gestation.
An agent for treatment of preeclampsia for use in a pregnant human female subject exhibiting a ratio of CD44/FKBPL:
- a) greater than a predetermined threshold in a biological sample therefrom, wherein the sample is from 15-30 weeks gestation, or
- b) lower than a second predetermined threshold wherein the sample is from 30 or more weeks gestation.
Dependencies are inferred from the claim text.